An analysis of the results of the CANTOS trial published in 2019 suggested that targeted anti‐cytokine therapy with the anti‐IL‐1β monoclonal antibody canakinumab reduces hospitalization and mortality in patients with prior myocardial infarction with or without heart failure through the inhibition of IL‐1β signalling.169. The gene discussed is IL1B; the disease is heart failure.